[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560873":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":41,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Lidocaine infusion",null,"Patients will receive a 100 mg intravenous lidocaine bolus followed by an initial infusion at a rate of 2 mg∙kg -1∙h-1 based on ideal body weight. Lidocaine infusions will continue for a minimum of 1 h post-bolus. If headache numeric pain score decreases at all after initiation of infusion, then the rate will drop to 1 mg∙kg -1∙h-1. If headache numeric pain score starts increasing again, then the rate will return to 2 mg∙kg -1∙h-1, otherwise it will remain at 1 mg∙kg -1∙h-1 for up to 48 h.",[13],{"name":14,"affiliation":5,"role":15},"Fernando Salgado, MD","PRINCIPAL_INVESTIGATOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"William L Krogman, MS","CONTACT","316-268-6156","wkrogman@kumc.edu",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Ascension Via Christi St. Francis","RECRUITING","Wichita","Kansas","67214","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-97.33754,37.69224,{"lat":35,"lon":34},[38,39],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},{"name":14,"role":19,"phone":10,"phoneExt":10,"email":40},"fsalgado33@kumc.edu",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[44],{"name":45,"class":46},"Ascension Health","INDUSTRY","100560873","lidocaine-infusion-treatment-for-subarachnoid-hemorrhage-headaches-100560873",false,"NCT06582810","Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches","Lidocaine Infusion As A Treatment Modality For Headache Following Non-Traumatic Subarachnoid Hemorrhage: A Prospective, Single-Center, Observational Cohort Study","Inclusion Criteria:\n\n* Patients \\> 18 years;\n* Have a favorable neurological status defined as Hunt and Hess score ≤ 3 (as it accounts for patient awareness);\n* Can communicate numeric pain scores;\n* Are diagnosed with non-traumatic subarachnoid hemorrhage\n\nExclusion Criteria:\n\n* The patient is diagnosed with traumatic subarachnoid hemorrhage;\n* If the patient is \\\u003C 18 years of age;\n* If numeric pain scores could not be captured for \\> 3 days of hospitalization;\n* If the patient had a prior aneurysm;\n* Chronic pain not associated with non-traumatic subarachnoid hemorrhage diagnosis;\n* A disability before the stroke (\\> 2 on modified Rankin Scale score);\n* A Hunt and Hess score \\> 3;\n* Contraindications to lidocaine (significant cardiac disease, arrhythmia, seizures, previous allergic reaction to lidocaine","ALL","18 Years",{"count":57,"type":58},20,"ESTIMATED","7 Days","OBSERVATIONAL","The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to:\n\n1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate\u002Fsevere headache pain following non-traumatic subarachnoid hemorrhage;\n2. show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage;\n3. and report vasospasm prevalence in the cohort.\n\nParticipants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours the patients are awake for a maximum of seven days. Monitoring for vasospasm will occur as part of the patients regular medical care.",[63,64],"Subarachnoid; Hemorrhage, Nontraumatic","Headache",[66,64,67],"Nontraumatic Subarachnoid Hemorrhage","Lidocaine Infusion","2026-07-08",{"date":70,"type":71},"2026-07-10","ACTUAL",{"date":73,"type":71},"2025-01-31",{"date":75,"type":58},"2028-07",{"name":5,"class":6},1]